BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16329139)

  • 1. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Hitt R; Amador ML; Quintela-Fandino M; Jimeno A; del Val O; Hernando S; Cortes-Funes H
    Cancer; 2006 Jan; 106(1):106-11. PubMed ID: 16329139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Specenier P; Rasschaert M; Vroman P; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Am J Clin Oncol; 2011 Oct; 34(5):472-7. PubMed ID: 20938321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.
    Guardiola E; Peyrade F; Chaigneau L; Cupissol D; Tchiknavorian X; Bompas E; Madroszyk A; Ronchin P; Schneider M; Bleuze JP; Blay JY; Pivot X
    Eur J Cancer; 2004 Sep; 40(14):2071-6. PubMed ID: 15341981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.
    Guntinas-Lichius O; Appenrodt S; Veelken F; Krug B
    Laryngoscope; 2006 Apr; 116(4):613-8. PubMed ID: 16585868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck.
    Cho BC; Keum KC; Shin SJ; Choi HJ; Lee YJ; Kim SH; Choi EC; Kim JH
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):27-32. PubMed ID: 19381630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
    Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin.
    Park Y; Kim DS; Park KH; Baek SK; Kwon SY; Shin SW; Jung KY; Kim CY; Kim YH; Lee NJ; Kim JS; Kim IS
    Onkologie; 2012; 35(11):673-82. PubMed ID: 23147544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
    Couteau C; Chouaki N; Leyvraz S; Oulid-Aissa D; Lebecq A; Domenge C; Groult V; Bordessoule S; Janot F; De Forni M; Armand JP
    Br J Cancer; 1999 Oct; 81(3):457-62. PubMed ID: 10507770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck.
    Fujii M; Tsukuda M; Satake B; Kubota A; Kida A; Kohno N; Okami K; Inuyama Y;
    Int J Clin Oncol; 2004 Apr; 9(2):107-12. PubMed ID: 15108042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Zenda S; Onozawa Y; Boku N; Iida Y; Ebihara M; Onitsuka T
    Jpn J Clin Oncol; 2007 Jul; 37(7):477-81. PubMed ID: 17720737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
    Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
    Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
    Knoedler M; Gauler TC; Gruenwald V; Matzdorff A; Schroeder M; Dietz A; Jordan WO; Arnold D; Hennemann B; Hofele C; Weissinger F; Eberhardt W; Keilholz U
    Oncology; 2013; 84(5):284-9. PubMed ID: 23445718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer.
    Tahara M; Minami H; Hasegawa Y; Tomita K; Watanabe A; Nibu K; Fujii M; Onozawa Y; Kurono Y; Sagae D; Seriu T; Tsukuda M
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):769-76. PubMed ID: 21181475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
    Pearl ML; Johnston CM; McMeekin DS
    Gynecol Obstet Invest; 2007; 64(4):193-8. PubMed ID: 17664880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Baghi M; Hambek M; Wagenblast J; May A; Gstoettner W; Knecht R
    Anticancer Res; 2006; 26(1B):585-90. PubMed ID: 16739325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
    Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.